Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 12/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4673547 | 0.81 | TACR1 (0.44) | SMOTACR1MCHR1CYP3A4 | |
| SCHEMBL4672291 | 0.81 | TACR1 (0.43) | SMOTACR1CYP3A4TYK2 | |
| SCHEMBL6286992 | 0.79 | PTPN11 (0.50) | — | |
| SCHEMBL905364 | 0.78 | TACR1 (0.57) | SMOTACR1CYP3A4 | |
| SCHEMBL905379 | 0.77 | CYP1A2 (0.54) | TACR1JAK1TYK2PIK3CD | |
| SCHEMBL905377 | 0.77 | TACR1 (0.45) | SMOTACR1PIK3CD | |
| SCHEMBL7137826 | 0.76 | TACR1 (0.47) | SMOTACR1 | |
| SCHEMBL905365 | 0.76 | TACR1 (0.49) | SMOTACR1PIK3CD | |
| SCHEMBL905356 | 0.73 | TACR1 (0.44) | SMOTACR1 | |
| SCHEMBL13684919 | 0.72 | KCNH2 (0.43) | KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303490-B1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-6897226-B2 | NK-1 receptor active amine oxide prodrugs | HOFFMANN-LA ROCHE INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-6806370-B2 | NEUROKININ-1 RECEPTOR ANTAGONISTS ARE FURTHER USEFUL FOR THE TREATMENT OF MOTION SICKNESS AND FOR TREATMENT INDUCED VOMITING | HOFFMANN-LA ROCHE INC. | 2004-10-19 | — | — | US | disclosed |
| US-6747026-B2 | FOR THERAPY OF DISEASE RESPONSIVE TO ANTAGONIST MODULATION OF THE NEUROKININ-1 (NK-1) RECEPTOR IN A PATIENT | HOFFMAN-LA ROCHE INC. | 2004-06-08 | — | — | US | disclosed |
| US-20040048901-A1 | NK-1 receptor active amine oxide prodrugs | HOFFMANN TORSTEN (DE) | 2004-03-11 | — | — | US | disclosed |
| EP-1394150-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-20040014793-A1 | NK-1 receptor active amine oxide prodrugs | HOFFMANN TORSTEN (DE) | 2004-01-22 | — | — | US | disclosed |
| US-20030149039-A1 | For therapy of disease responsive to antagonist modulation of the Neurokinin-1 (NK-1) receptor in a patient | HOFFMANN TORSTEN (DE) | 2003-08-07 | — | — | US | disclosed |
| US-6593472-B2 | Antiinflammatory, -arthritic and -emetic agents; central nervous system disorders; Parkinson's disease; antidepressants; psychological disorders; anxiolytic agents; antagonists of substance P receptors | HOFFMAN-LA ROCHE INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1303490-A1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6479483-B2 | 3,4,6-SUBSTITUTED PYRIDINE DERIVATIVES USEFUL FOR TREATING DEPRESSION AND PAIN, RESULTING FROM INFLAMMATORY CONDITIONS, SUCH AS MIGRAINE, RHEUMATOID ARTHRITIS, ASTHMA AND INFLAMATORY BOWEL DISEASE; NK1 RECEPTOR ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | BOS MICHAEL (CA) | 2002-07-11 | — | — | US | disclosed |
| US-20020045642-A1 | NK-1 receptor active amine oxide prodrugs | HOFFMANN-LA ROCHE INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2002006236-A1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048901-A1 | NK-1 receptor active amine oxide prodrugs | TACR1, BDKRB1, NPSR1 | SMO 3223/4885TACR1 1/4885KCNH2 283/4885 |
| US-20040014793-A1 | NK-1 receptor active amine oxide prodrugs | TACR1, BDKRB1, NPSR1 | SMO 3223/4885TACR1 1/4885KCNH2 283/4885 |
| US-20030149039-A1 | For therapy of disease responsive to antagonist modulation of the Neurokinin-1 (NK-1) receptor in a patient | BDKRB2, BDKRB1, TACR1 | SMO 3213/4885TACR1 3/4885KCNH2 222/4885 |
| US-20020045642-A1 | NK-1 receptor active amine oxide prodrugs | TACR1, BDKRB1, NPSR1 | SMO 3223/4885TACR1 1/4885KCNH2 283/4885 |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | CBR1, CBR3, HCCS | SMO 3742/4885TACR1 534/4885KCNH2 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.